Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
25/03/2026 15:09
March 25 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK: FY LOSS ATTRIBUTABLE RMB218.6 MILLION FY REVENUE RMB154.3 MILLION Further company coverage: 1541.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S